Arrowhead Pharmaceuticals heads into its August 7 earnings report with the most bullish analyst consensus momentum it has seen in months, even as short sellers quietly pare back positions.
The analyst signal is the standout here. Every major upgrade in recent weeks has moved in the same direction — upward. Morgan Stanley lifted its Overweight target to $120 from $100 on July 23. Piper Sandler raised to $126. B. Riley Securities pushed to $123 just last week. JP Morgan took its target to $95 in mid-July. Stifel initiated coverage at $98 with a Buy. Across the board, the Street has been marking up price objectives ahead of the print, with the consensus target now around $108 — roughly 21% above the current $89.59 close. The analyst recommendation divergence factor ranks in the 92nd percentile of the ORTEX universe, a sign that the bullish lean among covering analysts is unusually uniform right now.
The bull case centres on Arrowhead's RNAi pipeline — REDEMPLO and zodasiran chief among the assets — and the commercial and financial support the Novartis partnership provides. Bears point to the pre-profitability reality: the company runs a negative PE and EV/EBITDA, carries meaningful clinical trial risk across multiple programs, and has periodically needed to access capital markets. The price-to-book has expanded sharply over the past month to over 34x, so execution expectations embedded in the stock are high even after the recent gains.
Short sellers have been stepping back for weeks, and that retreat is now quite pronounced. Short interest has dropped nearly 29% over the past month to about 6.6% of the free float — still meaningful for a biotech, but the trend is clearly toward covering rather than pressing. Borrow conditions offer no squeeze catalyst: availability is exceptionally loose at nearly 3,900% of short interest, meaning shares to borrow are plentiful, and cost to borrow is running at just 0.51%. The lending market is firmly in the "plenty of supply" zone. Options positioning has shifted modestly more defensive over the past two weeks — the put/call ratio of 0.65 is above its 20-day average of 0.55 — but at less than one standard deviation above the mean, it reads as mild caution rather than a hedge against a sharp move. The stock itself is up about 7% over the past month to $89.59, part of a broader year-to-date rally of roughly 30%.
One institutional detail worth noting: BlackRock added over 550,000 shares through to June 30, lifting its stake to just above 10% of the company. FMR (Fidelity) added around 747,000 shares over the same period. Both moves suggest the largest passive and active institutional holders were building into the rally rather than trimming.
The print will test whether the pipeline progress underlying those analyst target hikes — and the institutional accumulation — is supported by the clinical and financial data the company delivers on August 7.
See the live data behind this article on ORTEX.
Open ARWR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
